There are 124 posts and answers and impossible to post all. In essence, the vaccine made significant differences in her symptoms. Try google "im-enrolled-in-the-vical-study-ama-ask-me-anything".
If you search the same forum, there are genocea posts as well. Genocea worked for some patients, but there are two cases of severe side effects (the ceo also responded to the patient).
As for the Vical poster, hope she's doing even better after the third injection. Evidently, not many participants posted as the stigma of herpes may have prevented many. We should all appreciate her sharing. Hope that effective treatment is not far.
Yahoo deletes my reply if I have a link. Google "im-enrolled-in-the-vical-study-ama-ask-me-anything" and you should see the link.
There's no crossover. It's open label study. All the patients knew what they are getting. the central data base did not know until final analysis.
It's all about statistics. So far all the p values are not statistically significant (p 0.05). Remember that the results from the P2 trial on ovarian cancer was even better than this one on NSCLC and P3 on ovarian failed.
The patent covers prescription usage if ever approved. Look at AMRN (fish oil). AMRN has the patent, but consumers don't have to buy from them and insurance could refuse to cover if alternative cheaper bio-equivalent available.
The 8mg does available in supplemental stores in Mexico and Canada for about $15 a month. By the way, Zinc cysteine available at GNC.
COMBI-v (GSK combo) and co-BRIM will be presented back to back for direct comparison and discussions at ESMO as presidential symposium at ESMO on 29th. Winner will be most likely the dominant combo for treating V600 mutant melanoma in 2016 and beyond in combination with anti-PD1 with global sales approaching 1B. Loser will be marginalized.
No direct connection whatsoever. However, the statement indicates that BRAF inhibitor (or combo such as from GSK or Roche) still has a place in melanoma (V600 mutants) in immunotherapy.
Could be. I believe Roche combo will be superior from reading the press release of Roche: they will seek approval of the combo world-wide. If inferior, Roche might not have said that. Remember that GSK have to initially withdraw their application of its combo from the European agency.
Excellent post. If confirmed in COBRIM, then vemurafenib+cobimetinib combo will become standard of care with V600 mutants. Details will be presented in ESMO as the last major presentation (29th 4:45pm, one of four Presidential symposiums). PFS 13.7 to 9.4 months should translate into 1.7 to 2 months overall survival advantage in melanoma.
Evidently, Cabo did not improve survival. However, it does no harm either regarding survival and produce significant progression free survival (double). If comet-2 impresses, will FDA approve it for pain management? Especially if negotiated by, say, Roche?
Yahoo would not allow me to post links (thanks a million!). There is some evidence that cabo is used off label. It is said to work really well for bone pain. Go to healingWell website and search cometriq and you can read the discussions.
Similar comments from CEOs of Vical, Oncogenex and others before crashing.
Feel your pain. I still remember that OGXI spinned its failed phase 2 (OGX-011, failed its primary end point PFS) into a success and even got some money from TEVA. Of course, Phase 3 just failed. A failed trial is a failed trial. What happened to ZINC cysteine and Alzheimer's and other junk? Same-O same-O.
Compare to the P2 trial in ovarian trial, the HR (0.75) is really disappointing. The HRs in PFS for cancer drugs are generally much better than 0.7 (Zytiga, Xtandi or any other recently approved oncology drugs). Hope the HR in OS could reach 0.75 or better (P2 ovarian HR about 1.0).